

Multiple Sclerosis (MS) Clinically Isolated Syndrome (CIS)

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

Trial Status
Active, not recruiting

Trial Runs In
5 Countries

Trial Identifier
NCT04998812 2021-000062-14
MN42988

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT04998812 2021-000062-14 MN42988
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
>=18 Years & <= 40 Years

Healthy Volunteers
No
